Table 1.
Clinical correlation of miR-410-3p expression in cancer patients
| miR-410-3p | ||||
|---|---|---|---|---|
| Features | Low (n = 30) | Higha (n = 30) | t/χ2 | P |
| Gender | 4.8 | 0.028 | ||
| Male | 16 | 24 | ||
| Female | 14 | 6 | ||
| Age (years) | 0.606 | 0.436 | ||
| > 65 | 12 | 15 | ||
| ≤ 65 | 18 | 15 | ||
| Tumor stage | 8.531 | 0.003 | ||
| I + II | 17 | 6 | ||
| III + IV | 13 | 24 | ||
| Weight (kg) | 62.3 ± 8.06 | 59.73 ± 11.6 | 0.834 | 0.410 |
| BMI (kg/m2) | 22.6 ± 2.55 | 21.71 ± 2.2 | 1.144 | 0.260 |
| Body weight loss (%) | 0.23 ± 0.09 | 9.76 ± 4.12 | 11.862 | < 0.001 |
| IL-6 (pg/mL) | 3.81 ± 1.78 | 6.96 ± 2.74 | 2.385 | 0.024 |
| TNF-a (pg/mL) | 9.57 ± 5.98 | 12.45 ± 7.83 | 1.164 | 0.253 |
| TP (g/L) | 65.21 ± 5.44 | 64.27 ± 4.77 | 0.57 | 0.574 |
| ALB (g/L) | 41.57 ± 4.41 | 39.1 ± 3.92 | 1.947 | 0.044 |
aAccording to the median expression level of miR-410-3p in all patients, the expression with lower than 50th percentile was classified as low expression group; the patients with higher than 50th percentile was classified as high expression group